Xth Eurasian Hematology-Oncology Congress
I

Bone Marrow Allogenic Transplantation in Relapsed/ Refractory Hem Malignancies: IO Is Effective Bridging Strategy, and to Treat Relapses After HSCT, alloHSCT Technology Is Improving

By Xth Eurasian Hematology-Oncology Congress FEATURING Ivan Moiseev
By Xth Eurasian Hematology-Oncology Congress FEATURING Ivan Moiseev
11 views
December 13, 2019
0 Comments
Login to view comments. Click here to Login

Featured Video

13:04
Winship Cancer Institute - Emory University

Treatment-Related Quality of Life in MF

Feat. A. Hunter

Featured Video

06:51
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…

Feat. D. Tremblay

Related Content

AUTOPLAY
21:05
Louisville Hematology Highlights

Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Feat. R. Gale
06:23
Integrity Continuing Education

ASH 2023 Insights: "PERSEUS Study - Daratumumab With VRd vs. VR…

Feat. O. Landgren
05:47
Meletios Dimopoulos

PERSEUS Study Primary Results: Daratumumab + VRd vs. VRd Alone in Pa…

05:56
ASH 2022 Conference Coverage

ASH 2022 Myeloma XI Trial: Defining the Optimal Duration of Lenalido…

Feat. G. Morgan
40:21
Fred Hutch 13th Annual Comprehensive Hematology & Oncology Review Course

Overview of Hematopoietic Cell Transplantation

Feat. R. Salit
13:05
Moffitt Cancer Center

Newly Diagnosed Myeloma: Why We Should Use a Response-Adapted Approa…

Feat. K. Shain
18:27
Indy Hematology Review

DEBATE: Why Not to Transplant When MRD Has Been Achieved After Initi…

Feat. J. Mikhael
52:39
Yale Cancer Center

Myeloma in 2023: So Many Drugs, Yet So Few Cures

Feat. A. Chari
41:54
University of Colorado Division of Hematology

Overview of Pathophysiology, Diagnosis and Management of Multiple My…

Feat. K. Sidor
21:11
MyCancerHaven

Experts Discuss the Future of Stem Cell Transplantation in Myeloma

Feat. R. Vij, N. Callander
13:55
Moffitt Cancer Center

Newly Diagnosed Myeloma: Why We Should NOT Use a Response-Adapted Ap…

Feat. O. Castañeda-Puglianini
15:49
SOHO 2023 Eleventh Annual Meeting

SOHO 2023 DEBATE: Early HDM-aSCT in MM Is No Longer the SoC

Feat. C. Mo
15:53
Indy Hematology Review

DEBATE: Transplanting the MRD- Myeloma Patients for a Deeper Remissi…

Feat. S. Usmani
11:56
SOHO 2023 Eleventh Annual Meeting

SOHO 2023 DEBATE: Upfront HCT for Newly Diagnosed Multiple Myeloma

Feat. N. Callander
15:53
Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient

Managing Newly Diagnosed Myeloma in 2024

Feat. A. Garfall
05:38
GRACE

Overview on Current Immunotherapy Options in Myeloma

Feat. S. Rajeeve
37:04
Nebraska Oncology Society

Survivorship After Transplant and CAR-T for Hematologic Malignancies

Feat. N. Ahmed
17:42
UChicago Medicine

CAR-T and BiTE Therapy in Myeloma

Feat. R. Malloy
24:19
Dana-Farber Cancer Institute

Phase 3 DETERMINATION Trial: RVd ± ASCT & Lenalidomide Maintenan…

Feat. P. Richardson
07:28
GRACE

Overview and Logistics of Bone Marrow Transplant

Feat. M. Ruiz